Skystar Bio Pharmaceutical Company reported consolidated earnings results for the year ended December 31, 2012. For the year, the company reported revenue, net was $33,586,791,000 against $52,788,279 for the same period in the last year. Income from operations was $8,550,981 against $15,249,924 for the same period in the last year. Income before provision for income taxes was $8,380,553 against $16,528,939 for the same period in the last year. Net income was $6,212,428 against $13,657,640 for the same period in the last year. Basic and diluted earnings per share were $0.83 against $1.90 for the same period in the last year. Net cash provided by operating activities was $5,612,124 against net cash used in operating activities of $1,658,937 for the same period in the last year. Purchases of property, plant and equipment were $163,049 against $524,574 for the same period in the last year. Payments on construction-in-progress were $393,032 against $7,028,129 for the same period in the last year.

The company provided earnings guidance for the fiscal 2013. The company currently anticipates delivering a 20% to 35% year over year increase in top line revenue. The expected revenue range is $40 million to $45 million with gross margin of roughly 50% for the fiscal 2013. This view takes into consideration revenues from facilities that have come online following GMP recertification.